In any case, from these data, it is not feasible to determine if a real benefit exists for the melanoma V600K subgroups or if the reported results are tied to the most numerous subgroup (V600E) or to other factors, such as PDL-1 expression, that may consistently influence all the findings. This evidence concerns the gene CD274 and melanoma.